arrow
C

Christopher Mallow

Albert Einstein College of Medicine
H指数:27
被引数:4,258

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus

成人呼吸道合胞病毒感染的多重共病模式与院内严重预后

2025-08-010
PRE
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024

疫苗对流感A(H1N1)、A(H3N2)和B相关住院的效力,美国,2023年9月1日至2024年5月31日

2025-04-080
PRE
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination

与呼吸道合胞病毒疫苗接种相关的患者层面和社区层面特征

2025-04-010
OA
COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United 2019-2022

2019-2022年美国住院成人中COVID-19和流感疫苗犹豫现象

VACCINE
IF3.5
2025-02-010
PRE
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study

早期奥司他韦治疗对甲型流感住院成人患者的益处: 一项观察性研究

2024-11-281
OA
Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023

2022年9月-2023年8月,原始单价和二价新型冠状病毒肺炎疫苗对美国成人COVID-19-Associated住院和严重住院结局的有效性

2024-11-040
OA
Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism

原始单价信使RNA冠状病毒疾病2019 (新型冠状病毒肺炎) 疫苗接种系列对COVID-19-Associated静脉血栓栓塞住院的有效性

2024-10-150
PRE
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024

更新的2023-2024 (单价XBB.1.5) 新型冠状病毒肺炎接种SARS-CoV-2 Omicron XBB和BA.2.86/JN.1的有效性谱系住院和临床严重程度的比较-IVY Network,26家医院,2023年10月18日-2024 3月9日

2024-08-069
OA
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023

疫苗对甲型流感相关住院,器官衰竭和死亡的有效性: 美国,2022-2023

2023-12-0519
OA
Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules

用于不确定肺结节分层的生物标志物的更新

CHEST
IF8.6
2023-10-0110
PRE
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022

引入新型冠状病毒肺炎疫苗后,美国冠状病毒疾病2019 (新型冠状病毒肺炎) 住院成人严重程度和流行病学的变化,3月2021-2022年8月

2023-05-3125
OA
Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants

感染SARS-CoV-2 α,δ 和Omicron变体的患者的总和亚基因组RNA病毒载量

2023-03-086
OA
Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022
2022-12-3111
OAAI
Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022
2022-11-0315
OA
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

在美国,主要系列和加强剂量对新型冠状病毒肺炎相关住院的疫苗有效性: living test阴性设计研究

2022-10-1156
OAAI
Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness
2022-07-1119
OA
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States
2022-07-0912
OA
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Ad26.cov2.s (强生公司) 冠状病毒疾病2019 (新型冠状病毒肺炎) 疫苗在美国预防新型冠状病毒肺炎住院和进展为高度疾病严重程度的有效性

2022-06-089
OA